Horizon Pharma plc (HZNP) - NASDAQ
  • Fri, Jul. 15, 7:16 AM
    • Mead Johnson Nutrition (NYSE:MJN) upgraded to Neutral from Underperform with a $96 (5% upside) price target by Bank of America.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $74 (21% upside) from $55.
    • Wright Medical Group (NASDAQ:WMGI) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $26 (21% upside) from $21.
    • Horizon Pharma (NASDAQ:HZNP) upgraded to Equal Weight from Underweight with a $24 (28% upside) price target by Morgan Stanley.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Outperform from Neutral by Credit Suisse. Price target lowered to $165 (32% upside) from $185.
    • HeartWare International (NASDAQ:HTWR) downgraded to Market Perform from Outperform with a $58 (1% upside) price target by Leerink Swann.
    | Fri, Jul. 15, 7:16 AM | 2 Comments
  • Fri, Jul. 1, 10:08 AM
    • Invitae (NYSE:NVTA) initiated with Hold rating with an $8.50 (18% upside) price target by Benchmark.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Outperform rating and $190 (33% upside) price target by BMO.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Underperform rating and $36 (4% upside) price target by BMO.
    • Mallinckrodt (NYSE:MNK) initiated with Outperform rating and $84 (35% upside) price target by BMO.
    • Horizon Pharma plc (NASDAQ:HZNP) initiated with Outperform rating and $29 (71% upside) price target by BMO.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) initiated with an Outperform rating and $400 (13% upside) price target by Bernstein.
    • Biogen (NASDAQ:BIIB) initiated with an Outperform rating and $282 (15% upside) price target by Bernstein.
    • Amgen (NASDAQ:AMGN) initiated with Market Perform rating and $161 (5% upside) price target by Bernstein.
    • Lannett Company (NYSE:LCI) initiated with Hold rating and $26 (5% upside) price target by Deutsche Bank.
    • OpGen (NASDAQ:OPGN) initiated with Buy rating and $2.50 (66% upside) price target by Rodman & Renshaw.
    • Valeant Pharmaceuticals (NYSE:VRX) initiated with Market Perform rating and $26 (22% upside) price target by BMO.
    • Neurocrine Biosciences (NASDAQ:NBIX) initiated with Outperform rating and $80 (75% upside) price target by H.C. Wainwright.
    • Healthstream (NASDAQ:HSTM) initiated with Outperform rating and $30 (12% upside) price target by Barrington Research.
    • Neurometrix (NASDAQ:NURO) initiated with Buy rating and $4.50 (165% upside) price target by Rodman & Renshaw.
    • Vascular Biogenics (NASDAQ:VBLT) initiated with Buy rating and $11 (139% upside) price target by H.C. Wainwright.
    | Fri, Jul. 1, 10:08 AM | 6 Comments
  • Wed, Jun. 29, 9:14 AM
    • Horizon Pharma (NASDAQ:HZNP) announces that it has submitted a supplemental New Drug Application (sNDA) with the FDA for RAVICTI (glycerol phenylbutyrate) Oral Liquid to expand the age range for chronic management of urea cycle disorders (UCDs) in adult and pediatric patients from two years of age to two months of age and older.
    • RAVICTI is currently indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients greater than two years of age with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
    • In addition, Horizon recently partnered with Clinigen Group's Idis Managed Access division to initiate a Managed Access Program in select European countries for eligible, individual patients living with UCDs. RAVICTI was approved in Europe in November 2015.
    | Wed, Jun. 29, 9:14 AM
  • Tue, Jun. 28, 9:18 AM
    | Tue, Jun. 28, 9:18 AM
  • Tue, Jun. 28, 2:57 AM
    • Endo International (NASDAQ:ENDP) has held discussions with P-E firms about potential asset sales to reduce its more than $8B debt pile.
    • Pfizer (NYSE:PFE) is investing $350M to build its first biotech center in China.
    • Horizon Pharma (NASDAQ:HZNP) has hired Bank of America to help it explore selling a significant equity stake that would bolster its balance sheet.
    | Tue, Jun. 28, 2:57 AM | 2 Comments
  • Fri, Jun. 10, 7:19 AM
    • Boston Scientific (NYSE:BSX) initiated with Buy rating and $26 (13% upside) price target by Guggenheim Securities.
    • Zimmer Biomet Holdings (NYSE:ZBH) initiated with Neutral rating and $140 (18% upside) price target by Guggenheim Securities.
    • Edwards Lifesciences (NYSE:EW) initiated with Neutral rating and $120 (18% upside) price target by Guggenheim Securities.
    • Oncobiologics (Pending:ONS) initiated with Buy rating and $15 (218% upside) price target by Cantor Fitzgerald.
    • Walgreens Boots Alliance (NASDAQ:WBA) reinstated with Buy rating and $95 (20% upside) price target by Bank of America.
    • Goldman Sachs initiates coverage of specialty pharma with a Neutral rating: Buy: Jazz Pharma (NASDAQ:JAZZ) - $196 (26% upside) price target, Horizon Pharma (NASDAQ:HZNP) - $24 (30% upside) price target; Neutral: Endo International (NASDAQ:ENDP) - $20 (11% upside) price target, Mallinckrodt (NYSE:MNK) - $73 (17% upside) price target, Momenta Pharmaceuticals (NASDAQ:MNTA) - $14 (19% upside) price target; Concordia Healthcare (NASDAQ:CXRX) - $32 (31% upside) price target; Sell: Impax Laboratories (NASDAQ:IPXL) - $33 (2% downside risk) price target.
    • Biocept (NASDAQ:BIOC) initiated with Buy rating and $1.20 (71% upside) price target by Roth Capital.
    • Seres Therapeutics (NASDAQ:MCRB) initiated with Outperform rating and $40 (22% upside) price target by Cowen & Company.
    • Omeros (NASDAQ:OMER) initiated with Buy rating and $21 (94% upside) price target by Cantor Fitzgerald.
    • Glaukos (NYSE:GKOS) initiated with Buy rating and $35 (30% upside) price target by Cantor Fitzgerald.
    • Shire plc (NASDAQ:SHPG) initiated with Overweight rating and GBX5,600 (34% upside) price target by Morgan Stanley.
    | Fri, Jun. 10, 7:19 AM
  • Thu, May 19, 8:27 AM
    • Horizon Pharma plc (NASDAQ:HZNP) acquires the rights to interferon gamma-1b, marketed under the brand names IMUKIN, IMUKINE, IMMUKIN and IMMUKINE, from Boehringer Ingelheim International GmbH. The products are sold in 30 countries in Europe and the Middle East.
    • Under the terms of the agreement, Boehringer will receive €5M upon signing and €20M upon closing, expected to occur by year end. Horizon will own global rights to the products except the U.S., Canada and Japan.
    • In a separate deal, Horizon licensed the U.S. Canadian and European rights for interferon gamma-1b for the treatment Friedreich's ataxia to an undisclosed third party.
    • Horizon will immediately begin investing in manufacturing, supply chain, regulatory and commercial activities to support the new business. The investments will trim ~$10M from its 2016 EBITDA guidance.
    | Thu, May 19, 8:27 AM
  • Mon, May 9, 9:41 AM
    • Horizon Pharma (HZNP +12.3%) Q1 results: Revenues: $204.7M (+81.0%); R&D Expense: $12.7M (+104.8%); SG&A: $141.9M (+93.6%); Operating Loss: ($27.2M) (-666.7%); Net Loss: ($45.4M) (-131.6%); Loss Per Share: ($0.28) (-75.0%); Non-GAAP EPS: $0.34 (+88.9%); Quick Assets: $385.9M (-55.1%); CF Ops: $54.2M (+176.7%).
    • 2016 Guidance: Net Sales: $1.025B - 1.050B; Adjusted EBITDA: $505M - 520M.
    | Mon, May 9, 9:41 AM | 4 Comments
  • Mon, May 9, 9:14 AM
    | Mon, May 9, 9:14 AM
  • Mon, May 9, 7:17 AM
    • Horizon Pharma (NASDAQ:HZNP): Q1 EPS of $0.34 beats by $0.04.
    • Revenue of $204.7M (+80.9% Y/Y) beats by $6.97M.
    • Press Release
    | Mon, May 9, 7:17 AM | 2 Comments
  • Sun, May 8, 5:30 PM
    | Sun, May 8, 5:30 PM | 15 Comments
  • Mon, Apr. 25, 12:07 PM
    • In a regulatory filing, Depomed (DEPO -0.3%) reports that, by mutual agreement, it has ended its legal fight with Horizon Pharma (HZNP -3%) stemming from the latter's unsolicited hostile offer and its alleged misuse of confidential information related to NUCYNTA (tapentadol). Both firms agreed to settle their respective claims against each other.
    • Horizon also agreed to maintain the confidentiality of applicable information related to NUCYNTA that it received from Janssen Pharmaceuticals and not use said information. It also committed to not initiate another hostile bid for Depomed through January 1, 2020.
    | Mon, Apr. 25, 12:07 PM
  • Tue, Apr. 12, 12:45 PM
    | Tue, Apr. 12, 12:45 PM | 5 Comments
  • Tue, Apr. 12, 9:12 AM
    | Tue, Apr. 12, 9:12 AM
  • Tue, Apr. 12, 8:47 AM
    • Horizon Pharma (NASDAQ:HZNP) is down 8% premarket on increased volume in apparent response to its corporate presentation filed with the SEC this morning.
    • Slide #9 states revenue expectations for 2016 are $1.025B - 1.050B (+37% at midpoint), in line with the consensus view of $1.03B. The company appears to be a bit slippery with its quarterly guidance, however. Instead of presenting its top-line expectations as it does for the year, it provides (Slide #11) only percentages. Doing the math for Q1, its guidance range is ~$195M - 210M, below the consensus view of $228M.
    • Read now Horizon Pharma Remains Undervalued
    | Tue, Apr. 12, 8:47 AM | 16 Comments
  • Tue, Mar. 22, 5:41 PM
    • Top gainers, as of 5.25 p.m.: AFFX +5.1%. SCS +5.0%. DF +2.7%.ODP +2.3%. HZNP +2.0%.
    • Top losers, as of 5.25p.m.: BTU -5.6%. KKD -5.4%. SHLX -5.2%. INSY -4.7%. FIVE -4.5%.
    | Tue, Mar. 22, 5:41 PM
Company Description
Horizon Pharma Plc is a specialty biopharmaceutical company, which engages in the business of identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. It markets a portfolio of products in arthritis, inflammation and orphan diseases. The... More
Sector: Healthcare
Industry: Biotechnology
Country: United States